Global Intrauterine Contraceptive Devices (IUCD) Market Size By Type (Non-hormonal, Hormonal), By Application (T Shapes, V Shapes), By Region, And Segment Forecasts, 2023 to 2032

The Global Intrauterine Contraceptive Devices (IUCD) Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 7.9 billion by 2031, growing at a CAGR of 7.7% during the forecast period of 2023–2031. The market's growth is driven by increasing awareness regarding long-term and reversible contraception, rising initiatives by governments and NGOs to promote family planning, and growing concerns about unplanned pregnancies globally. IUCDs offer a cost-effective and highly efficient method of birth control, gaining popularity especially in developing countries with expanding reproductive health programs.

Drivers:

1. Rising Awareness of Long-Term Contraception:

As more women seek non-hormonal, long-acting, and reversible contraceptive solutions, IUCDs are gaining traction as a reliable alternative to oral pills and other short-term methods.

2. Government and NGO Family Planning Programs:

Numerous public health initiatives and subsidized contraceptive programs are significantly boosting the adoption of IUCDs, particularly in regions with high population growth rates.

3. Technological Advancements in IUCD Design:

Improvements such as smaller sizes, hormone-releasing variants, and lower expulsion rates are increasing the comfort, efficacy, and acceptance of IUCDs among users worldwide.

Restraints:

1. Risk of Side Effects and Medical Complications:

Concerns around side effects such as irregular bleeding, pelvic infections, and uterine perforation remain barriers to IUCD adoption, particularly among first-time users.

2. Limited Access in Rural Areas:

In many low-income and remote regions, lack of access to skilled healthcare providers and proper facilities for IUCD insertion and removal affects market penetration.

Opportunity:

1. Expansion in Emerging Markets:

The increasing availability of healthcare infrastructure and targeted awareness campaigns in Asia-Pacific, Latin America, and Africa are expected to unlock substantial market potential.

2. Rising Demand for Hormonal IUCDs:

Hormonal IUCDs, which offer additional benefits such as reduced menstrual bleeding and pain, are becoming increasingly popular, especially among urban populations seeking dual benefits.

Market by System Type Insights:

Hormonal IUCDs dominated the global market in 2023, accounting for the largest revenue share. These devices not only offer high contraceptive efficacy but also provide therapeutic benefits such as menstrual regulation, making them the preferred choice among healthcare providers and users alike. However, Copper IUCDs continue to hold significant market share due to their hormone-free formulation and cost-effectiveness, particularly in public health programs.

Market by End-use Insights:

The Hospitals and Clinics segment led the market in 2023, driven by high patient footfall, availability of trained professionals, and the integration of IUCD insertion with broader reproductive health services. The Community Health Centers segment is anticipated to witness rapid growth, especially in rural areas, due to expanding government initiatives and improved primary care delivery systems.

Market by Regional Insights:

Asia-Pacific emerged as the largest regional market in 2023, supported by strong family planning campaigns, rising awareness levels, and high population density in countries such as India and China. North America followed closely, benefiting from high healthcare expenditure and favorable insurance coverage for contraceptive devices. Meanwhile, Africa and Latin America are expected to experience robust growth due to increasing international funding and healthcare outreach programs.

Competitive Scenario:

Leading players in the global IUCD market include Bayer AG, Teva Pharmaceutical Industries Ltd., CooperSurgical, Inc., Medicines360, Pregna International Ltd., and DKT International. Companies are focusing on product innovations, affordability, and strategic partnerships with health organizations to expand their reach. For example:

In 2023, Bayer expanded access to its Mirena hormonal IUCD through a public-private partnership initiative in Sub-Saharan Africa.

In 2024, CooperSurgical announced a next-generation IUCD with enhanced comfort and ease of insertion, aimed at increasing uptake among young women.

DKT International strengthened its distribution network in Southeast Asia in 2023 to support community-level family planning efforts.

Scope of Work – Global Intrauterine Contraceptive Devices (IUCD) Market

Report Metric Details

Market Size (2023) USD 4.3 billion

Projected Market Size (2031) USD 7.9 billion

CAGR (2023–2031) 7.7%

Market Segments By System Type (Hormonal IUCD, Copper IUCD), By End-use (Hospitals & Clinics, Community Health Centers), By Region

Growth Drivers Awareness of long-acting reversible contraception, Government & NGO programs, Technological improvements

Opportunities Expansion in emerging markets, Hormonal IUCD innovations

Key Market Developments:

May 2023: Bayer AG partnered with global NGOs to distribute Mirena across rural Africa.

September 2024: Teva launched a cost-effective hormonal IUCD targeted at middle-income markets.

January 2025: Pregna International introduced a mobile IUCD training platform for health workers in South Asia.

FAQs:

1. What is the current market size of the Global Intrauterine Contraceptive Devices (IUCD) Market?

The market was valued at USD 4.3 billion in 2023.

2. What is the major growth driver of the Global Intrauterine Contraceptive Devices (IUCD) Market?

Key drivers include growing awareness of long-acting contraception and increased